ClinicalTrials.gg
RecruitingNCT03809728i-BANKUpdated Feb 7, 2024

IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE

An interventional study of endoscopic biopsy and samples of the oral cavity in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France — 2 open to participants now, 2 under way, none of them phase 3. Inflammatory Bowel Diseases · Central Hospital, Nancy, France.

Started
2019
the only one that year
No phase
2 of 10
1 open now
Registered
3rd of 10
by date

Among the 10 studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France, this one is the only one that started in 2019, is one of 2 with no phase, and was the 3rd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

2 of the 10 studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Inflammatory Bowel Diseases by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

Interventional study of a group of patients with an inflammatory bowel disease (IBD; Crohn's disease (CD) or ulcerative colitis (UC)) to identify predictive and prognostic biomarkers of natural history and response to biotherapies.

Read the detailed description

Percentage of primary responders who haven't lost response to biotherapies during follow-up (anti-TNF, ustekinumab, vedolizumab).

Response to treatment will be evaluated using objective criteria for measuring intestinal inflammation: endoscopic remission (endoscopic biopsy and surgical specimens), radiological (MRI), and / or biological (CRP, fecal calprotectin) .

Response to therapy rates will be correlated with genomic, epigenomic, and microbiota data stratified by major environmental factors (nutrition, tobacco, physical activity).

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>=18 years
  • Patients with an established diagnosis of CD or UC (clinical, biological, radiological, endoscopic or histologic criteria)
  • Patients >=45 kg
  • Affiliated member of the Social Security system

Exclusion criteria

Exclusion Criteria:

  • Patients with an undetermined colitis
  • Patients with a non established diagnosis of CD
  • Women of childbearing age without a method of
  • Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code
  • Pregnant women, breastfeeding women

    -- Age \< 18 years

  • Persons under legal protection
  • Person who does not have the capacity to consent
  • Persons under the age of 18 years who are deprived of their liberty by decision of a judicial or administrative authority (articles L. 3212-1 and L. 3213-1).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Other
    IBD patients

    All patients with an established Crohn's disease or ulcerative colitis

    Procedure: endoscopic biopsy · Procedure: samples of the oral cavity · Procedure: Samples of the resected specimen

Interventions

  • Procedureendoscopic biopsy

    Per-endoscopic biopsies

  • Proceduresamples of the oral cavity

    7 samples of the oral cavity with a swab

  • ProcedureSamples of the resected specimen

    if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised

06

What researchers measure

Primary outcomes

  1. Proportion of patients who have lost response to biotherapies (anti-TNF, ustekinumab, vedolizumab).

    Time frame: 5 years

Secondary outcomes

  1. Proportion of patients who underwent surgery

    Time frame: 5 years

  2. Post-operative morbidity rates in IBD

    Time frame: 5 years

  3. Surgical recurrent rate in Crohn's disease

    Time frame: 5 years

  4. Proportion of patients with a destruction of the intestinal wall in CD (abscess, fistula)

    Time frame: 5 years

  5. Proportion of patients developing a cancer

    Time frame: 5 years

  6. Readmission rates for acute severe colitis or ileitis

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • CHRU Nancy
    Vandœuvre-lès-Nancy, 54510, France
    Recruiting
    • Marine BECK · Contactm.beck@chru-nancy.fr · +33383155280
    • Laurent PEYRIN-BIROULET, MD, PhD · Sub investigator
    • Adeline GERMAIN, MD,PhD · Principal investigator
    • Laurent BRESLER, MD · Sub investigator
    • Camille ZALLOT, MD · Sub investigator
    • Marine FERRY, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Dec 2034, 180 months after the start.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 180 months is above that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2019
First posted
Jan 18, 2019
StartActual
Dec 10, 2019
Primary completionEst.
Dec 10, 2034
CompletionEst.
Dec 10, 2034
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03809728
Responsible party
Dr Laurent PEYRIN-BIROULET (Doctor, Central Hospital, Nancy, France) — Principal investigator
First posted
Jan 18, 2019
Start date
Dec 10, 2019
Primary completion
Dec 10, 2034 (estimated)
Completion
Dec 10, 2034 (estimated)
Last update
Feb 7, 2024

Study contacts

Adeline GERMAIN, MD, PhD
Contact
a.germain@chru-nancy.fr
+33383153120
Adeline GERMAIN, MD, PhD
principal investigator · CHRU Nancy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion